Corthera

Corthera Inc. is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for diseases in acute care settings. Corthera’s lead product candidate, relaxin, is currently being evaluated in a global Phase 2/3 clinical trial for acute decompensated heart failure. Corthera holds global rights to the development and commercialization of relaxin.